

Table S2a

PDX 4031 (PCNSL)	MYD88 Exon5 ENST00000396334: 19 (794) [chr3:g.38182641 (hg19)] c.794T>C, p.Leu265Pro VAF 47% (5228 reads) COSM85940 (COSMIC), rs387907272 (1000Genomes; dbSNP; gnomAD)
PDX 4113 (PCNSL)	CD79A Exon4,Exon5 ENST00000221972: -2..43 / 45bp [chr19:g.42384932_42384976 / 42384928_42384972 (hg19)] c.568- 2_610delAGGGCCTGAACCTGGACGACTGCTCCATGTATGAGGACATCTCCC, VAF 46% (3243 reads) MYD88 Exon5 ENST00000396334: 19 (794) [chr3:g.38182641 (hg19)] c.794T>C, p.Leu265Pro VAF 100% (10158 reads) COSM85940 (COSMIC), rs387907272 (1000Genomes; dbSNP; gnomAD)

VAF=variant allele frequency,

Table S2a: Targeted next generation sequencing of PCNSL PDX 4031 and 4113. Spleen xenograft lymphoma cells from PCNSL PDX 4031 and 4113 after i.s. implantation were analyzed with targeted next generation sequencing. Both PDX showed MYD88 p.Leu265Pro mutations and PDX 4113 had an additional CD79A mutation.

Table S2b

List of genes in lymphoid panel:

Gene	Target Region (exon)	Gene	Target Region (exon)	Gene	Target Region (exon)	Gene	Target Region (exon)
ATM	Full CDS	CXCR4	3	NFKBIE	1	SOCS1	2
B2M	1	EGR2	2	NOTCH1	26 - 28, 34	STAT3	7, 19 - 22
BIRC3	6 - 9	EZH2	12, 16, 18	NOTCH2	26, 27, 34	STAT5B	14 - 18
BRAF	15	GNA13	Full CDS	PLCG1	11	TCF3	17
BTK	15	ID3	1	PLCG2	19, 20, 24	TET2	7-11
CARD11	5-9	IDH2	4	POT1	4 - 7, 9	TNFAIP3	Full CDS
CD79A	2-5	JAK3	Full CDS	RHOA	2-5	TNFRSF14	Full CDS
CD79B	2-5	KLF2	Full CDS	RPS15	4	TP53	Full CDS
CIITA	1, 2, 15 - 19	MAP2K1	2-3	RRAGC	1, 2	TRAF3	5, 10
CREBBP	Full CDS	MYD88	Full CDS	SF3B1	14 - 16, 18	XPO1	15, 16

CDS=coding DNA sequence